Drug Trial Radar · NCT04709913
Multiple Ascending Dose Study of HU6 in High BMI Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 4, 2021
Primary completion
Apr 30, 2021
Study completion Jul 30, 2021
Sponsor
- Lead sponsor
- Rivus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 14-day multiple ascending dose trial in high BMI volunteers in up to 4 cohorts of 10 high BMI volunteers each consisting of 8 receiving HU6 and 2 receiving placebo. Upon review of the safety and PK data, it may be decided to expand the current cohort size and/or dose escalate to the next cohort. In addition, the sponsor may elect not to enroll all 4 cohorts based on safety and/or PK and/or PD data, or enlist an additional cohort at a higher dose if deemed safe.
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
HU6Drug
HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the dose relationship of PK Parameter CmaxTime frame: 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prism Clinical Research
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.